Back to "Semaglutide significantly reduced risk (..."
Claim
Strong Support
causal
Analysis v3

In adults with heart failure, semaglutide and liraglutide lower the risk of death from cardiovascular causes, while tirzepatide and exenatide do not lower this risk.

52
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

Semaglutide and liraglutide stick to heart cell receptors longer, turning on a signal that helps the heart use energy better and survive. Tirzepatide and exenatide bind briefly and do not turn on this signal long enough to help the heart survive.

Most probable mechanism

In Simple Terms

Semaglutide and liraglutide bind to heart cells' GLP-1 receptors for a longer time, which turns on a specific energy-saving signal inside the cells, helping the heart pump more efficiently and survive stress. Tirzepatide and exenatide bind differently and do not sustain this signal long enough to improve heart survival.

Causal chain
1

Semaglutide and liraglutide bind to GLP-1 receptors on cardiomyocytes with prolonged residence time, sustaining Gs-protein activation

Indirect evidence only
which leads to
2

Sustained Gs-protein activation elevates intracellular cAMP levels in cardiac myocytes, activating protein kinase A

Indirect evidence only
which leads to
3

Protein kinase A phosphorylates calcium-handling proteins, improving sarcoplasmic reticulum calcium reuptake and reducing diastolic stress

Indirect evidence only
which leads to
4

Enhanced calcium handling increases myocardial energy efficiency and reduces ATP depletion during heart failure stress

Indirect evidence only
which leads to
5

Tirzepatide and exenatide bind GLP-1 receptors with shorter residence time, failing to sustain cAMP elevation beyond transient thresholds

Indirect evidence only
which leads to
6

Transient cAMP signaling does not sufficiently modulate calcium handling or energy utilization to improve cardiomyocyte survival under chronic stress

Indirect evidence only

Evidence from Studies

Supporting (1)

52

Community contributions welcome

52

Abstract 4368175: GLP-1 Analogues and Cardiovascular Outcomes in Heart Failure Patients: A Network Meta-Analysis

Systematic Review With Meta-Analysis
Human

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Abstract 4368175: GLP-1 Analogues and Cardiovascular Outcomes in Heart Failure Patients: A Network Meta-Analysis

Score: 52
DOI: 10.1161/circ.152.suppl_3.4368175

Similar Assertions

Different GLP-1 receptor agonist drugs have different effects on cardiovascular outcomes; liraglutide and semaglutide are linked to cardiovascular benefit, while lixisenatide and exenatide are not.

33
0
87%

In adults with heart failure, semaglutide lowers the risk of death from cardiovascular causes by 28% compared to placebo.

52
0
86%

Liraglutide and exenatide, drugs that activate GLP-1 receptors, lower the frequency of heart attacks, strokes, and hospitalizations for heart failure by acting directly on the heart and metabolism, regardless of whether they cause weight loss.

38
52
80%

In adults with heart failure, none of the GLP-1 receptor agonist drugs have been shown to lower the rate of serious heart-related events like heart attack or stroke compared to a placebo, even though tirzepatide and dulaglutide performed better than other drugs in the studies.

52
0
78%

Semaglutide might be better than other similar weight-loss drugs at protecting heart health in people who are overweight or obese but don’t have diabetes.

65
0
78%